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 ABSTRACT
Objective. To describe clinical experience with edaravone 
in ALS over a period of 12 months 
Methods. The current study retrospectively investigated 
characteristics in a group of patients (n=31) with ALS who 
underwent edaravone treatment. Information including 
age, gender, race, and site of onset of symptoms were col-
lected for all patients. Adverse events with edaravone thera-
py was documented where available. 
Results. The average age of the patients observed was 
62.09 years, with 18 males and 13 females. 18 patients had 
limb onset, 12 bulbar onset, and 1 diaphragmatic onset. 7 
of the 31 patients discontinued treatment at the end of one 
year. The average age of patients who discontinued eda-
ravone was 65.71 years, of whom which 3 had limb onset, 3 
bulbar onset, and 1 diaphragmatic onset. No perceived ben-
efit, port complications, systemic bacteremia, and develop-
ment of atrial fibrillation were documented as reasons for 
discontinuation of therapy.
Conclusion. Edaravone is well tolerated in ALS patients 
at the end of one year. Lack of perceived benefit and port 
related complications are common reasons for discontinu-
ation of treatment
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive 
neurodegenerative disorder affecting upper and lower mo-
tor neurons throughout the nervous system, resulting in 
gradual paralysis and death in 3-5 years from onset.1 ALS 
presents in the 50s to 60s and is the most common neuro-
degenerative disorder of midlife, with one to two new cases 
per 100,000 people per year.1-3 The exact etiology of ALS 
is unknown, but it is thought to be attributed to the diverse, 
complex, and combined mechanisms involved in protein, 
RNA, and cytoskeletal homeostasis which are influenced 
by both genetic and environmental factors.1 The presence 
of oxidative stress has been credited to initiating many of 
these cellular changes and agreed to be, at least in part, re-
sponsible for the onset and progression of ALS.4-7
Despite avid research in the field and over 50 random-
ized controlled trials testing therapies for ALS, treatment 
is currently limited to only two FDA-approved drugs that 
may improve survival by merely a few months.5, 9 Riluzole, 
approved in 1995, was the first medication to be used for 
ALS treatment. It is thought elicit its therapeutic effects by 
suppressing excitatory neurotransmitter release. A second 
drug, edaravone was approved for ALS treatment in May 
2017 and slows ALS progression by acting as an antioxi-
dant to reduce free radical damage.1 Edaravone was origi-
nally marketed in Japan in 2001 as a drug to eliminate lipid 
peroxides and hydroxyl radicals in order to protect neurons 
from free radical damage during and acutely after cerebral 
infarction.10-13 Mitsubishi Tanabe Pharma Corporation (To-
kyo, Japan) then began investigating edaravone as an ALS 
treatment. The initial randomized controlled trial conduct-
ed failed to find statistically significant benefit, but post-hoc 
analysis and secondary clinical trials demonstrated that 
edarvone slowed progression of ALS in a subset of patients, 
evaluated using ALS Functional Rating Scale (ALSFRS-R) 
scores.14-16 These Japanese studies led to Edaravone’s even-
tual approval in the United States in May 2017. Criticisms of 
the trials include the narrow parameters of the study popu-
lation and the short duration of the trials.9 Because edara-
vone is a relatively new drug there is minimal data from U.S. 
studies on patient outcomes and perspectives, and because 
the original randomized controlled trials were only con-
ducted over six-month time periods, long-term effects of 
the drug are essentially unknown.
Edaravone treatment is a time-intensive process for 
the patient and his or her caregiver(s). The drug is admin-
istered via intravenous infusion daily for 14 days, followed 
by a 14-day break period, and then repeated infinitely until 
the patient decides to discontinue the medication or dies 
from his or her neurodegenerative disease. IV infusion re-
quires travel to an infusion center or presence of a home 
health nurse to administer the medication. Many obstacles 
face patients receiving edaravone treatment, including in-
surance approval of the medication, extended distances to 
infusion centers costing patients valuable time and money, 
insurance approval of home healthcare services, and guilt 
surrounding the caregiver’s use of time and resources. 
Materials and Methods
This study is a retrospective chart review of patients at-
tending a University-based hospital approved by the Insti-
tutional Review Board (IRB). The study population includ-
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ed patients with ALS who were undergoing care through 
University of Missouri Health Care. 
These patients started on edaravone for management 
of symptoms due to ALS by the same physician were includ-
ed in the study. Information including age, gender, race, site 
of onset of symptoms, ALSFRS-R score, FVC and FEV1/
FVC were collected for all of these patients. Adverse events 
with treatment where available were documented.
The analysis of the data included summarizing patient 
demographics and changes in FVC in form of descriptive 
statistical variables including mean, standard deviation, 
ranges and percentages. Comparison of FVC and ALSFRS-
R at different intervals was done by using Wilcoxon signed 
rank test. All statistical analyses were done using SPSS v22 
software (IBM, Armonk, NY). 
Results
The entire cohort participating in the study consisted 
of 31 patients with a mean age of 62.09±8.97 years and 
58.04% of the patients had the onset of the disease as the 
lower limb making it the most common site of origin in our 
cohort. 54.8% of these patients were found to suffice the El 
Escorial criteria of definite disease. The demographics and 
clinical profile of these patients is summarized in Table 1.
of 65.71±9.15 years and the reasons of discontinuation of 
the drug included no perceived benefit by the intervention 
(28.5%) and port site complications (28.5%) amongst oth-
er reasons. The reasons why the drug was discontinued are 
summarized in Table 2. 
Discussion
Seven of our thirty-one patients, nearly one-quarter, 
started on edaravone for ALS discontinued treatment by 
one year of therapy. Reasons for discontinuation included 
no perceived benefit of treatment by patient and adverse 
events. Adverse events included port site complications 
(dermatitis and redness around the port), systemic bactere-
mia, and atrial fibrillation. We are unable to determine if the 
adverse events which influenced discontinuation are related 
to edaravone administration. Of the adverse events record-
ed in our patients, dermatitis is the only established adverse 
reaction, and has been reported in 8% of patients.16-18 Bacte-
remia is common among patients with frequently accessed 
medication ports, like those receiving daily edaravone injec-
tions 14 days each month.19 Atrial fibrillation is secondary 
to a plethora of cardiac and non-cardiac causes and risk 
factors, and thus is a nonspecific occurrence. Meta-analysis 
by Lou et al indicated that prevalence of adverse events was 
similar in patients receiving edaravone and those receiving 
a placebo.20 This may suggest that adverse events prompt-
ing discontinuation may be more closely linked to patients’ 
predisposing factors.
Of those who discontinued treatment, 28.57% did not 
determine the drug was effective. We sought to determine 
reasoning for this perception. This retrospective cohort 
study found no association between patient characteristics 
(i.e. sex, race, onset location, El Escorial Criteria diagnosis) 
and discontinuation status. We have hypothesized several 
direct and indirect factors which may have contributed to 
impression of drug ineffectiveness, including difficulty of in-
Average age 62.09±8.97 years
Sex
Male 18
Female 13
Race
White 30
African American 1
Onset location  
Lower Limb 18
Bulbar 12
Diaphragm 1
El Escorial Criteria
Definite 17
Probable 12
Possible 1
Table 1: A summary of the characteristics of patients included 
in the study.
Out of the 31 patients enrolled in the study, 7 of patients 
discontinued the drug. These patients had the average age 
Reason for Discontinuation Number of Patients who Discontinued
No perceived benefit 2
 Atrial fibrillation 1
Port site complications  
Port migration 1
Port site reaction 1
Systemic bacteremia 2
Table 2: Reasons for discontinuation of drug amongst the 
seven patients.
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fusion process, medication cost, and presence of advanced 
disease. Development of an orally administered form of 
edaravone may shift perspectives by eliminating infusion 
process difficulties.21-22
Judging therapeutic interventions as clinically or sta-
tistically significant can be difficult for complex, mortifer-
ous diseases such as ALS. With lack of serum biomarkers 
to track disease progress, it is difficult to determine which 
measures of a disease (i.e. ALSFRS-R, pulmonary function 
testing, etc.) are most accurate and representative. To en-
hance analysis of ALS treatments, we propose employing 
patient opinion of effectiveness as an additional assessment 
when determining clinical significance because it is a valu-
able part of treatment success.
Limitations to our study stem from its retrospective 
nature. We had no control over cohort assignment or data 
collection. This may have introduced bias into aspects of 
our data. 
In conclusion, when considering edaravone treatment 
physicians should balance the therapeutic effect, experi-
ence of adverse events, and patient perspective of benefit.
Correspondence: Raghav Govindarajan,
govindarajanr@health.missouri.edu
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